National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer
Paper cited by one bottleneck page and 15 idea pages, indexed on Europe PMC as PubMed record 28820644 and published in Journal of Clinical Oncology; the citing pages link this DOI, which is how the record was matched.
Overview
Purpose In the United States, 3.8 million women have a history of breast (BC) or ovarian cancer (OC). Up to 15% of cases are attributable to heritable mutations, which, if identified, provide critical knowledge for treatment and preventive care. It is unknown how many patients who are at high risk for these mutations have not been tested and how rates vary by risk criteria. Methods We used pooled cross-sectional data from three Cancer Control Modules (2005, 2010, 2015) of the National Health Interview Survey, a national in-person household interview survey. Eligible patients were adult females with a history of BC and/or OC meeting select 2017 National Comprehensive Cancer Network eligibility criteria on the basis of age of diagnosis and family history. Outcomes included the proportion of individuals reporting a history of discussing genetic testing with a health professional, being advised to undergo genetic testing, or undergoing genetic testing for BC or OC. Results Of 47,218 women, 2.7% had a BC history and 0.4% had an OC history. For BC, 35.6% met one or more select eligibility criteria; of those, 29.0% discussed, 20.2% were advised to undergo, and 15.3% underwent genetic testing. Testing rates for individual eligibility criteria ranged from 6.2% (relative with OC) to 18.2% (diagnosis ≤ 45 years of age). For OC, 15.1% discussed, 13.1% were advised to undergo, and 10.5% underwent testing. Using only four BC eligibility criteria and all patients with OC, an estimated 1.2 to 1.3 million individuals failed to receive testing. Conclusion Fewer than one in five individuals with a history of BC or OC meeting select National Cancer Comprehensive Network criteria have undergone genetic testing. Most have never discussed testing with a health care provider. Large national efforts are warranted to address this unmet need.
Indexed on Europe PMC as PubMed record 28820644 (DOI 10.1200/jco.2017.73.6314). Matched by DOI alone: one bottleneck page and 15 idea pages cite this DOI among their external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.
One bottleneck page and 15 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.
Similar pages
not linked directly; found by shared links- RoadmapCancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers
Shares Build polygenic scores that work in every ancestry before deploying any, Let clinics contact relatives directly when a cancer gene is found, A bone drug to prevent breast cancer in BRCA1 carriers, Get every Lynch syndrome carrier onto the right dose of aspirin.
- Key paperPROSE consortium: preventive surgery lowers cancer and death in BRCA1 and BRCA2 carriers
Shares A bone drug to prevent breast cancer in BRCA1 carriers, Population germline screening for hereditary cancer genes with cascade testing, Inherited risk is mostly unidentified.
- IdeaCancer interception vaccines for high-risk carriers
Shares A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval, A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers, Inherited risk is mostly unidentified.
- Key paperFirst trial of a vaccine against the shared neoantigens of mismatch-repair-deficient cancers
Shares A frameshift neoantigen vaccine for Lynch syndrome carriers as the first preventive cancer vaccine approval, A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers, Inherited risk is mostly unidentified.
- TechnologyGermline (hereditary) testing
Shares Family history collected by app and matched to testing criteria automatically, A chatbot for pre-test genetic counselling so counsellors see only who needs them, Ban life and disability insurers from using genetic results, Build polygenic scores that work in every ancestry before deploying any.
- CollectionClinVar
Shares Test every possible mutation in every cancer gene so no result is 'uncertain', Inherited risk is mostly unidentified.
- TermGermline vs somatic mutations
Shares Let clinics contact relatives directly when a cancer gene is found, Population germline screening for hereditary cancer genes with cascade testing, Automatic germline testing for every cancer type where it changes care, Inherited risk is mostly unidentified.
- Key paperCAPP2: two years of aspirin cuts bowel cancer in Lynch syndrome by more than a third over 10 years
Shares Get every Lynch syndrome carrier onto the right dose of aspirin, Inherited risk is mostly unidentified.